GO:0160082 hypoxia-inducible factor-proline dioxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0160082 describes the enzymatic activity that hydroxylates proline residues on hypoxia-inducible factor alpha (HIF-alpha) subunits, using 2-oxoglutarate (alpha-ketoglutarate), oxygen, and ascorbate as cofactors.
• This activity is the central oxygen-sensing step in the HIF pathway: when oxygen is available, prolyl hydroxylation tags HIF-alpha for degradation, and when oxygen is low, HIF-alpha escapes hydroxylation and activates hypoxia-response genes.
• The reaction produces succinate and carbon dioxide while converting 2-oxoglutarate to succinate, linking HIF regulation directly to central carbon metabolism.
• The oncometabolite 2-hydroxyglutarate competitively inhibits alpha-ketoglutarate-dependent dioxygenases, including HIF prolyl hydroxylases, thereby altering HIF stability in cancer.
• Pharmacological inhibition of HIF prolyl hydroxylase activity, for example by enarodustat, stabilizes HIF and is used to treat renal anemia.
• Metabolic signals such as beta-hydroxybutyrate and lactate can modulate PHD2 activity, connecting HIF prolyl hydroxylation to cardiac repair and adipose inflammation.
Description
Hypoxia-inducible factor-proline dioxygenase activity (GO:0160082) is a molecular function that catalyzes the hydroxylation of specific proline residues within the oxygen-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) subunits. This enzymatic activity requires 2-oxoglutarate (also called alpha-ketoglutarate), molecular oxygen, ferrous iron, and ascorbate, and it produces succinate and carbon dioxide as byproducts. Because the reaction consumes oxygen, it acts as a direct oxygen-sensing mechanism that controls HIF-alpha protein stability. In normoxia, prolyl hydroxylation of HIF-alpha creates a binding site for the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, leading to rapid ubiquitination and proteasomal degradation of HIF-alpha. Under hypoxia, the hydroxylation reaction is limited by oxygen availability, allowing HIF-alpha to accumulate, dimerize with HIF-beta, and activate transcription of genes involved in angiogenesis, erythropoiesis, and metabolism. This makes GO:0160082 a central node in oxygen homeostasis and a target for therapeutic modulation in ischemic and neoplastic diseases. Researchers study this activity to understand how cells adapt to low oxygen, how metabolic intermediates influence gene expression, and how pharmacological inhibitors can stabilize HIF for clinical benefit. The enzyme family includes PHD1, PHD2, and PHD3 (also known as EGLN2, EGLN1, and EGLN3), each with distinct tissue distribution and substrate preferences.
hypoxia-inducible factor-proline dioxygenase activity At A Glance
| GO ID | GO:0160082 |
|---|---|
| GO term | hypoxia-inducible factor-proline dioxygenase activity |
| Ontology | molecular_function |
| Synonym | HIF hydroxylase, HIF prolyl hydroxylase |
| Major function | Oxygen-dependent hydroxylation of proline residues on HIF-alpha subunits, tagging them for VHL-mediated degradation |
| Cofactors | 2-oxoglutarate (alpha-ketoglutarate), molecular oxygen, ferrous iron, ascorbate |
| Reaction products | CO2, succinate, trans-4-hydroxy-L-prolyl-HIF-alpha |
| Enzyme family | EGLN/PHD family (PHD1, PHD2, PHD3) |
| Substrate | L-prolyl-[hypoxia-inducible factor alpha subunit] |
| Biological context | Cellular oxygen sensing and HIF pathway regulation |
What Is GO:0160082?
GO:0160082, hypoxia-inducible factor-proline dioxygenase activity, is defined as the catalysis of the reaction: 2-oxoglutarate + L-prolyl-[hypoxia-inducible factor alpha subunit] + O2 = CO2 + succinate + trans-4-hydroxy-L-prolyl-[hypoxia-inducible factor alpha subunit]. In simpler terms, it is the oxygen-dependent enzymatic addition of a hydroxyl group to a proline residue on HIF-alpha, using alpha-ketoglutarate as a co-substrate and releasing succinate and carbon dioxide.
Why Is hypoxia-inducible factor-proline dioxygenase activity Important in Cell Biology?
GO:0160082 is important because it provides the primary biochemical link between oxygen availability and HIF-mediated transcriptional responses. By hydroxylating HIF-alpha, this activity sets the threshold for HIF stabilization and thereby controls genes involved in angiogenesis, erythropoiesis, glycolysis, and cell survival. Dysregulation of this activity contributes to cancer progression, ischemic injury, and metabolic disorders, and pharmacological inhibition of HIF prolyl hydroxylases is already a clinical strategy for treating renal anemia.
• Acts as the central oxygen sensor in the HIF pathway, controlling HIF-alpha stability.
• Links central carbon metabolism to gene regulation through 2-oxoglutarate consumption and succinate production.
• Is competitively inhibited by the oncometabolite 2-hydroxyglutarate, connecting cancer metabolism to HIF signaling.
• Pharmacological inhibition stabilizes HIF and is used to treat anemia in chronic kidney disease (e.g., enarodustat).
• Modulation by beta-hydroxybutyrate influences cardiac repair after myocardial infarction.
• Adipocyte-derived lactate targets PHD2 to potentiate adipose macrophage inflammation.
• PHD3 stimulates pyruvate kinase M2 as a coactivator for HIF-1, integrating glycolytic metabolism with HIF transactivation.
• Adipocyte HIF-2alpha, stabilized when PHD activity is low, suppresses atherosclerosis by promoting ceramide catabolism.
• Activation of the HIF pathway by PHD inhibition protects against acute ischemic stroke by reprogramming central carbon metabolism.
• Infection and alpha-ketoglutarate/oxygen inhibition converge on CDC20 to promote cancer cell aneuploidy, highlighting broader roles of alpha-ketoglutarate-dependent dioxygenases.
Molecular Mechanism of hypoxia-inducible factor-proline dioxygenase activity
Substrate recognition and binding
In simple terms: The enzyme finds and grabs the HIF-alpha protein at a specific proline spot.
HIF prolyl hydroxylases (PHD1, PHD2, PHD3) recognize the oxygen-dependent degradation domain of HIF-alpha subunits, which contains conserved proline residues (Pro402 and Pro564 in human HIF-1alpha). The enzymes use a double-stranded beta-helix (jelly-roll) fold to bind the substrate peptide in an extended conformation, positioning the target proline near the catalytic iron center.
Catalytic cycle and cofactor requirements
In simple terms: The enzyme uses oxygen, alpha-ketoglutarate, iron, and vitamin C to add a hydroxyl group to proline.
The catalytic cycle requires ferrous iron (Fe2+) in the active site, 2-oxoglutarate as a co-substrate, molecular oxygen, and ascorbate as a reducing agent. The reaction proceeds by oxidative decarboxylation of 2-oxoglutarate, generating a highly reactive ferryl intermediate that hydroxylates the proline residue, yielding succinate, CO2, and trans-4-hydroxy-L-prolyl-HIF-alpha.
Oxygen sensing and VHL recruitment
In simple terms: When oxygen is present, the hydroxyl mark tells the cell to destroy HIF-alpha; when oxygen is low, the mark is missing and HIF-alpha survives.
In normoxia, prolyl hydroxylation of HIF-alpha creates a hydroxyproline epitope that is recognized by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, leading to ubiquitination and proteasomal degradation of HIF-alpha. In hypoxia, the hydroxylation reaction is limited by oxygen availability, so HIF-alpha escapes degradation, accumulates, and activates transcription of hypoxia-response genes.
Metabolic regulation by 2-oxoglutarate and inhibitors
In simple terms: The enzyme's activity depends on the availability of alpha-ketoglutarate and can be blocked by similar molecules like 2-hydroxyglutarate.
Because 2-oxoglutarate is a co-substrate, changes in its cellular concentration directly affect HIF prolyl hydroxylase activity. The oncometabolite 2-hydroxyglutarate acts as a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases, including HIF prolyl hydroxylases, thereby stabilizing HIF and altering gene expression in cancer. Other metabolites, such as beta-hydroxybutyrate and lactate, can also modulate PHD2 activity in specific tissues.
Isoform-specific functions and regulation
In simple terms: Different versions of the enzyme (PHD1, PHD2, PHD3) have different jobs and are regulated differently.
PHD2 (EGLN1) is considered the primary oxygen sensor for HIF-1alpha, while PHD3 (EGLN3) can stimulate pyruvate kinase M2 as a coactivator for HIF-1, linking glycolytic metabolism to HIF transactivation. PHD1 (EGLN2) has distinct roles in adipose tissue and ischemic protection. The isoforms differ in tissue distribution, substrate preference, and regulation by metabolic signals.
Key Genes Involved in GO:0160082 hypoxia-inducible factor-proline dioxygenase activity
The following genes encode the enzymes, substrates, and regulatory proteins that directly participate in or modulate hypoxia-inducible factor-proline dioxygenase activity (GO:0160082).
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGLN1 (PHD2) | Primary prolyl hydroxylase for HIF-1alpha; oxygen sensor | Target for HIF stabilization in anemia and ischemia |
| EGLN2 (PHD1) | Prolyl hydroxylase with tissue-specific roles | Adipocyte HIF-2alpha regulation and atherosclerosis suppression |
| EGLN3 (PHD3) | Prolyl hydroxylase; stimulates PKM2 as HIF-1 coactivator | Links glycolysis to HIF transactivation |
| HIF1A | Substrate of prolyl hydroxylation; transcription factor | Central to hypoxia response and cancer metabolism |
| HIF2A (EPAS1) | Substrate of prolyl hydroxylation; transcription factor | Adipocyte ceramide catabolism and atherosclerosis |
| VHL | E3 ubiquitin ligase that recognizes hydroxyproline on HIF-alpha | Tumor suppressor; degradation of HIF-alpha |
| PKM2 | Pyruvate kinase M2; coactivator for HIF-1 stimulated by PHD3 | Glycolytic regulation of HIF transactivation |
| 2-OG (metabolite) | Co-substrate for prolyl hydroxylation | Links central carbon metabolism to HIF regulation |
| 2-HG (metabolite) | Competitive inhibitor of alpha-KG-dependent dioxygenases | Oncometabolite that stabilizes HIF in cancer |
| Beta-hydroxybutyrate | Metabolite that targets PHD2 | Cardiac repair after myocardial infarction |
| Lactate | Adipocyte-derived signal targeting PHD2 | Adipose macrophage inflammation |
| CDC20 | Cell cycle regulator affected by alpha-KG/oxygen inhibition | Cancer cell aneuploidy |
| Enarodustat | Pharmacological PHD inhibitor | Treatment of renal anemia |
| O2 (oxygen) | Substrate and limiting factor for the reaction | Oxygen sensing in ischemia and stroke |
| Ascorbate | Reducing agent required for catalytic cycle | Cofactor for dioxygenase activity |
| Fe2+ (iron) | Active-site metal ion | Essential for catalytic activity |
| Succinate | Product of the reaction | Metabolic byproduct linking to TCA cycle |
How Is hypoxia-inducible factor-proline dioxygenase activity Regulated?
HIF prolyl hydroxylase activity is regulated at multiple levels. Oxygen availability is the primary limiting factor, as molecular oxygen is a substrate for the reaction. The concentration of 2-oxoglutarate, a co-substrate, directly influences enzyme velocity, and competitive inhibitors such as 2-hydroxyglutarate can reduce activity. Metabolites including beta-hydroxybutyrate and lactate can modulate PHD2 activity in specific tissues. Additionally, PHD3 can stimulate pyruvate kinase M2 as a coactivator for HIF-1, providing a feedback link between glycolytic metabolism and HIF transactivation. Pharmacological inhibitors like enarodustat are designed to block this activity and stabilize HIF for therapeutic benefit.
hypoxia-inducible factor-proline dioxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGLN1 (PHD2) | Renal anemia; ischemia | PHD2 knockout or point-mutation cell models; enarodustat treatment |
| EGLN3 (PHD3) | Cancer metabolism; glycolysis | PHD3 knockout cells; PKM2 coactivator assays |
| HIF1A | Ischemic stroke; cancer | HIF1A knockout or knock-in of proline mutants |
| HIF2A (EPAS1) | Atherosclerosis; adipocyte biology | Adipocyte-specific HIF2A knockout or overexpression |
| VHL | Cancer (VHL syndrome) | VHL knockout cells; HIF-alpha stability assays |
Cancer and the Warburg effect
In cancer, altered metabolism can inhibit HIF prolyl hydroxylase activity, leading to HIF stabilization even in normoxia. The oncometabolite 2-hydroxyglutarate competitively inhibits alpha-ketoglutarate-dependent dioxygenases, including HIF prolyl hydroxylases, thereby promoting HIF-driven gene expression. PHD3 stimulates pyruvate kinase M2 as a coactivator for HIF-1, linking glycolytic metabolism to HIF transactivation in cancer cells. Infection and alpha-ketoglutarate/oxygen inhibition converge on CDC20 to promote cancer cell aneuploidy, further implicating this pathway in tumor progression.
Ischemic stroke and neuroprotection
Activation of the HIF pathway by inhibiting prolyl hydroxylase activity protects against acute ischemic stroke by reprogramming central carbon metabolism. This suggests that pharmacological inhibition of GO:0160082 could be a therapeutic strategy for ischemic injury.
Cardiovascular disease and cardiac repair
Beta-hydroxybutyrate facilitates postinfarction cardiac repair by targeting PHD2, indicating that modulation of HIF prolyl hydroxylase activity influences cardiac remodeling after myocardial infarction. Adipocyte HIF-2alpha, stabilized when PHD activity is low, suppresses atherosclerosis by promoting adipose ceramide catabolism.
Anemia and renal disease
Pharmacological inhibition of HIF prolyl hydroxylase activity with enarodustat stabilizes HIF and stimulates erythropoiesis, providing a treatment for renal anemia. This clinical application demonstrates the therapeutic potential of targeting GO:0160082.
From hypoxia-inducible factor-proline dioxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PHD2 stabilize HIF-1alpha in normoxia? | EGLN1 knockout cell line (e.g., HEK293 or cancer cells) |
| Does a specific proline residue on HIF-1alpha mediate VHL binding? | HIF1A point-mutation knock-in (Pro402Ala or Pro564Ala) |
| Can a tagged PHD2 be used to monitor substrate interaction? | Knock-in of FLAG- or HA-tagged EGLN1 |
| Does overexpression of PHD3 enhance PKM2 coactivator function? | EGLN3 overexpression in cancer cell lines |
| Does 2-hydroxyglutarate inhibit PHD activity in cells? | Cell models treated with 2-HG or IDH-mutant cells |
| Does enarodustat stabilize HIF and induce erythropoietin? | Hepatoma or renal cell lines treated with enarodustat |
How to Study the hypoxia-inducible factor-proline dioxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro hydroxylation assay | Enzymatic conversion of 2-OG to succinate and proline hydroxylation | Kinetic characterization of PHD isoforms |
| Western blot | HIF-alpha protein levels | Assessment of PHD inhibition or hypoxia |
| Co-immunoprecipitation | VHL-HIF-alpha interaction | Confirmation of hydroxylation-dependent binding |
| Mass spectrometry metabolomics | 2-OG, succinate, 2-HG levels | Metabolic regulation of PHD activity |
| CRISPR knockout screen | Genes affecting HIF stability | Discovery of novel regulators |
| Reporter gene assay | HIF transcriptional activity | High-throughput drug screening |
| qRT-PCR | HIF target gene expression (e.g., EPO, VEGF) | Functional validation of PHD inhibition |
| Prolyl hydroxylation-specific antibodies | Hydroxyproline on HIF-alpha | Direct detection of enzymatic activity |
In vitro hydroxylation assays
Recombinant PHD enzymes can be incubated with HIF-alpha peptide substrates, 2-oxoglutarate, Fe2+, ascorbate, and oxygen, and the reaction products (succinate, CO2, hydroxyproline) can be measured by mass spectrometry or coupled enzymatic assays.
HIF-alpha stability and VHL binding assays
Western blotting for HIF-1alpha or HIF-2alpha after treatment with PHD inhibitors or under hypoxia can assess changes in protein stability. Co-immunoprecipitation of VHL with hydroxylated HIF-alpha can confirm prolyl hydroxylation-dependent interaction.
Metabolite profiling
Mass spectrometry-based metabolomics can quantify 2-oxoglutarate, succinate, 2-hydroxyglutarate, and other metabolites to assess the metabolic context of PHD activity.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate HIF prolyl hydroxylase activity or HIF stability, using HIF-responsive reporter cell lines.
How CRISPR Can Be Used to Study GO:0160082 hypoxia-inducible factor-proline dioxygenase activity
Knockout
CRISPR knockout of EGLN1, EGLN2, or EGLN3 can eliminate specific prolyl hydroxylase activities, leading to HIF-alpha stabilization and activation of hypoxia-response genes even in normoxia. This approach is useful to dissect isoform-specific functions and to validate PHD enzymes as drug targets.
Point Mutation
Point mutations in the catalytic domain of PHD enzymes or in the proline hydroxylation sites of HIF-alpha (e.g., Pro402Ala, Pro564Ala) can be introduced by CRISPR to study substrate recognition and VHL binding. Such models help determine which proline residue is critical for degradation.
Knock-in
Knock-in of epitope tags (FLAG, HA) or fluorescent proteins into endogenous EGLN1 or HIF1A loci allows real-time monitoring of protein expression, localization, and interaction with binding partners. Knock-in of disease-associated mutations can model altered PHD activity in cancer or cardiovascular disease.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of PHD enzymes can enhance HIF-alpha hydroxylation and degradation, reducing HIF transcriptional output. Overexpression of PHD3 has been used to study its role in stimulating PKM2 as a HIF-1 coactivator.
How EDITGENE Supports hypoxia-inducible factor-proline dioxygenase activity Research
Researchers studying hypoxia-inducible factor-proline dioxygenase activity-related genes often need to determine whether a candidate gene is causally involved in HIF regulation, metabolic adaptation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to enable such investigations with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for hypoxia-inducible factor-proline dioxygenase activity research.
Frequently Asked Questions About hypoxia-inducible factor-proline dioxygenase activity
What is hypoxia-inducible factor-proline dioxygenase activity?
It is the enzymatic activity (GO:0160082) that hydroxylates proline residues on HIF-alpha subunits using oxygen and 2-oxoglutarate, tagging HIF-alpha for degradation.
What genes are involved in hypoxia-inducible factor-proline dioxygenase activity?
The main genes are EGLN1 (PHD2), EGLN2 (PHD1), and EGLN3 (PHD3), which encode the prolyl hydroxylase enzymes, as well as HIF1A and HIF2A (EPAS1) that encode the substrate HIF-alpha subunits.
How does hypoxia-inducible factor-proline dioxygenase activity work?
The enzyme uses oxygen and 2-oxoglutarate to add a hydroxyl group to proline residues on HIF-alpha; this modification recruits the VHL ubiquitin ligase, leading to HIF-alpha degradation in normoxia.
What diseases are associated with hypoxia-inducible factor-proline dioxygenase activity?
It is linked to cancer, ischemic stroke, cardiovascular disease, and renal anemia; pharmacological inhibition is used to treat anemia.
What are the substrates of hypoxia-inducible factor-proline dioxygenase?
The substrate is L-prolyl-[hypoxia-inducible factor alpha subunit], and the co-substrates are 2-oxoglutarate and molecular oxygen.
What are the products of the hypoxia-inducible factor-proline dioxygenase reaction?
The products are carbon dioxide, succinate, and trans-4-hydroxy-L-prolyl-[hypoxia-inducible factor alpha subunit].
How is hypoxia-inducible factor-proline dioxygenase activity regulated?
It is regulated by oxygen availability, 2-oxoglutarate levels, competitive inhibitors like 2-hydroxyglutarate, and metabolites such as beta-hydroxybutyrate and lactate.
What is the role of PHD2 in hypoxia-inducible factor-proline dioxygenase activity?
PHD2 (EGLN1) is the primary prolyl hydroxylase for HIF-1alpha and is considered the main oxygen sensor; its inhibition stabilizes HIF and is targeted for anemia treatment.
Can CRISPR be used to study hypoxia-inducible factor-proline dioxygenase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function of PHD enzymes and HIF-alpha in hypoxia signaling.
What are the clinical applications of targeting hypoxia-inducible factor-proline dioxygenase activity?
PHD inhibitors such as enarodustat are approved for renal anemia, and inhibition of this activity is being explored for ischemic stroke and cardiac repair.
Conclusion
GO:0160082, hypoxia-inducible factor-proline dioxygenase activity, is a fundamental oxygen-sensing enzymatic function that controls HIF-alpha stability and the broader hypoxia transcriptional program. Its dysregulation contributes to cancer, cardiovascular disease, and anemia, and its pharmacological modulation has already reached clinical practice. Continued research using CRISPR-based cell models and metabolic profiling will further elucidate its roles and therapeutic potential.
References
- 1. Zhang X et al.. 2019. Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism.. Cell Metab 30(5):937-951.e5 PMID: 31668872
- 2. Luo W et al.. 2011. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1.. Cell 145(5):732-44 PMID: 21620138
- 3. Madai S et al.. 2024. Activation of the hypoxia-inducible factor pathway protects against acute ischemic stroke by reprogramming central carbon metabolism.. Theranostics 14(7):2856-2880 PMID: 38773968
- 4. Xu W et al.. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.. Cancer Cell 19(1):17-30 PMID: 21251613
- 5. Wang C et al.. 2025. β-Hydroxybutyrate Facilitates Postinfarction Cardiac Repair via Targeting PHD2.. Circ Res 136(7):704-718 PMID: 39957619
- 6. Markham A. 2021. Enarodustat: First Approval.. Drugs 81(1):169-174 PMID: 33320297
- 7. Zhou YN et al.. 2026. Infection and α-ketoglutarate/oxygen inhibition converge to CDC20 to promote cancer cell aneuploidy.. Signal Transduct Target Ther 11(1) PMID: 42693088
- 8. Feng T et al.. 2022. Adipocyte-derived lactate is a signalling metabolite that potentiates adipose macrophage inflammation via targeting PHD2.. Nat Commun 13(1):5208 PMID: 36064857
